Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.0K
Viral Recombination00:57

Viral Recombination

23.3K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.3K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

177
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
177
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

176
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
176
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

161
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
161

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiological and Evolutionary Dynamics of Dengue Virus in Saudi Arabia: Insights from Three Decades of Molecular and Serological Surveillance.

International journal of molecular sciences·2026
Same author

GC-MS Characterization and Pharmacological Activities of Natural Products from <i>Vitex agnus-castus</i>.

Biomedicines·2026
Same author

Evaluation of Chemical Composition, Anticancer, Antioxidant, Antibacterial, and Antidiabetic Activities of <i>Peucephyllum schottii</i>.

International journal of molecular sciences·2026
Same author

Molecular Surveillance of Coronaviruses in Riyadh (2025-2026): Persistent Genotype C and Conserved N-Glycosylation Motifs in Human Coronavirus OC43.

International journal of molecular sciences·2026
Same author

Gene Expression Profiles of Inflammatory Mediators in Influenza A and B Virus Infections: Insights from Riyadh, Saudi Arabia (2020-2023).

Genes·2026
Same author

Genomic Characterization and Phylogenetic Analysis of <i>HA</i> and <i>NA</i> Genes of Influenza B Virus in Riyadh (2024-2025): Implications for Vaccine Strain Match.

Viruses·2026

Related Experiment Video

Updated: Jun 10, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.4K

ONCOLYTIC ACTIVITY OF HUMAN RESPIRATORY SYNCYTIAL VIRUS.

D Dahrizal1, Ibrahim M Aziz2, Gani Asa Dudin1

  • 1Politeknik Kesehatan Kemenkes Bengkulu, Indonesia.

Experimental Oncology
|October 13, 2024
PubMed
Summary

Oncolytic viruses (OVs), like human respiratory syncytial virus (RSV), show promise in cancer therapy by targeting tumors and stimulating immune responses. RSV demonstrates oncolytic activity in various cancer cells, suggesting its potential in personalized cancer treatment.

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

Related Experiment Videos

Last Updated: Jun 10, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.4K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

Area of Science:

  • Oncolytic virotherapy
  • Cancer immunology
  • Virology

Background:

  • Oncolytic viruses (OVs) are engineered viruses used in cancer therapy.
  • OVs offer tumor-specific killing and immune co-stimulation.
  • Human respiratory syncytial virus (RSV) is an RNA virus with demonstrated oncolytic activity.

Purpose of the Study:

  • To discuss the oncolytic activity of RSV.
  • To explore the potential of RSV in cancer therapy.
  • To highlight RSV's mechanisms of action against cancer cells.

Main Methods:

  • Review of preclinical studies on RSV's oncolytic activity.
  • Analysis of molecular pathways involved in RSV-induced cancer cell death (apoptosis, autophagy).
  • Examination of RSV's interaction with immune responses in the tumor microenvironment.

Main Results:

  • RSV induces cancer cell death via apoptosis, linked to NF-κB and STAT-1 signaling defects.
  • RSV triggers autophagy and apoptosis in cervical cancer cells through ROS-BAX and TNF-α pathways.
  • RSV has shown effectiveness in preclinical models of prostate, hepatocellular, and dermal cancers.

Conclusions:

  • RSV exhibits significant oncolytic potential across various cancer types.
  • RSV's mechanisms involve apoptosis and autophagy induction.
  • Combination therapies involving RSV may enhance treatment outcomes for patients with limited conventional therapy responses.